Selective COX-2 Inhibition by a Pterocarpus marsupium Extract Characterized by Pterostilbene, and its Activity in Healthy Human Volunteers

Abstract

In this study, an extract of Pterocarpus marsupium Roxb. containing pterostilbene has been evaluated for its PGE₂-inhibitory activity in LPS-stimulated PBMC. In addition, the COX-1/2 selective inhibitory activity of P. marsupium (PM) extract was investigated. Biological activity, as well as safety of PM extract was evaluated in healthy human volunteers. PM extract, pterostilbene and resveratrol inhibited PGE₂ production from LPS-stimulated human peripheral blood mononuclear cells (PBMC) with IC₅₀ values of 3.2 ± 1.3 μg/mL, 1.0 ± 0.6 μM and 3.2 ± 1.4 μM, respectively. When pterostilbene content of PM extract is calculated, PGE₂ production inhibition of PM extract is comparable to PGE₂ production inhibition of purified pterostilbene. Furthermore, in a COX-1 whole blood assay (WBA) PM extract was not effective while in a COX-2 WBA, PM extract decreased PGE₂ production indicating COX-2 specific inhibition. In healthy human volunteers, the oral use of 450 mg PM extract did not decrease PGE₂ production ex vivo in a WBA. Pterostilbene levels in serum were increased, but were 5-fold lower than the observed IC₅₀ for PGE₂ inhibition in LPS-stimulated PBMC. No changes from base-line of the safety parameters were observed and no extract-related adverse events occurred during the study.
In conclusion, this is the first study to describe the selective COX-2 inhibitory activity of a Pterocarpus marsupium extract. Moreover, the PGE₂ inhibitory activity of PM extract was related to its pterostilbene content. In humans, 450 mg PM extract resulted in elevated pterostilbene levels in serum, which were below the active concentration observed in vitro. In addition, short-term supplementation of 450 mg PM extract is considered to be a safe dose based on the long history of use, the absence of abnormal blood cell counts and blood chemistry values and the absence of extract-related adverse events. This strongly argues for a dose-finding study of PM extract in humans to corroborate the in vitro observed inhibitory activity on PGE₂ production in order to resolve the potential use of PM extract in inflammatory disorders and/or inflammatory pain.

Pterocarpus marsupium - Fabaceae - pterostilbene - resveratrol - PGE₂ - cyclooxygenase - healthy human volunteers

References

• 1 Holtzman M J, Turk J, Shornick L P. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells.  J Biol Chem. 1992;  267 21 438-45
• 2 Hla T, Neilson K. Human cyclooxygenase-2 cDNA.  Proc Natl Acad Sci USA. 1992;  89 7384-8
• 3 Chandrasekharan N V, Dai H, Roos K L, Evanson N K, Tomsik J, Elton T S, Simmons D L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.  Proc Natl Acad Sci USA. 2002;  99 13 926-31
• 4 Cryer B, Kimmey M B. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs.  Am J Med. 1998;  105 20S-30S
• 5 Vane J R. The Fight against rheumatism: From willow bark to COX-1 sparing drugs.  J Physiol Pharmacol. 2000;  51 573-86
• 6 Flower R J. The development of COX-2 inhibitors.  Nat Rev Drug Discov. 2003;  2 179-91
• 7 Martinez J, Moreno J J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production.  Biochem Pharmacol. 2000;  59 865-70
• 8 Subbaramaiah K, Michaluart P, Chung W J, Tanabe T, Telang N, Dannenberg A J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells.  Ann N Y Acad Sci. 1999;  889 214-23
• 9 Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W, Fong H H, Farnsworth N R, Kinghorn A D, Mehta R G, Moon R C, Pezzuto J M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 1997;  275 218-20
• 10 Szewczuk L M, Forti L, Stivala L A, Penning T M. Resveratrol is a peroxidase mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004: 22 727-34
• 11 Lodha R, Bagga A. Traditional Indian systems of medicine.  Ann Acad Med Singapore. 2000;  29 37-41
• 12 Grover J K, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential.  J Ethnopharmacol. 2002;  81 81-100
• 13 Saxena A, Vikram N K. Role of selected Indian plants in management of type 2 diabetes: A review. J Altern Complement Med 2004; 10 : 369 - 78. 
• 14 Warner T D, Giuliano F, Vojnovic I, Bukasa A, Mitchell J A, Vane J R. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis.  Proc Natl Acad Sci USA. 1999;  96 7563-8
• 15 Van Miert A S. Extrapolation of pharmacological and toxicological data based on metabolic weight.  Arch Exp Veterinarmed. 1989;  43 481-8
• 16 Rimando A M, Cuendet M, Desmarchelier C, Mehta R G, Pezzuto J M, Duke S O. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol.  J Agric Food Chem. 2002;  50 3453-7